News

Winstone’s Voice

Winstone in Seattle, 2005

As has been widely reported, we lost Winstone Zulu, a tireless advocate for TB/HIV (see more info at the TB Alliance and ACTION). I was lucky to have been able to work with Winstone over the years – his greeting was always a hearty: “So when are you coming to Zambia?” I had to laugh because he always seemed to be everywhere all at once, on a tireless global journey to promote TB/HIV awareness.

But he was tired – often exhausted from battling his illness, adverse reactions to therapy, and of course his punishing schedule. And yet, to know him was to marvel at his indomitable spirit, which rarely seemed to miss an opportunity to do some good in the world.

Chief among Winstone’s gifts was the ability to speak with passion about his subject, finding the precise balance between hard facts, personal history, and an inspiring call to action. In 2003, we collaborated on a video to raise awareness about TB/HIV co-infection. The title, “Winstone Zulu is Alive” came from a conversation in which Winstone explained that since the average life expectancy in Zambia was 40 (his figure), he was already living on borrowed time and it was important to remind people that he was still around.

Now that Winstone has passed, the title seems all the more poignant: if you listen to his profoundly moving voice, you realize that his spirit remains very much with us.

John-Michael Maas

Winstone Zulu boarding a ferry in Seattle, 2005

Make a donation to support Winstone’s family

RESULTS has set up an account to make donations to help support Winstone’s family. In order to alert RESULTS that your contribution is for the Winstone Zulu Memorial Fund, you must copy and paste “Winstone Zulu Memorial Fund” into the field that asks, “Who invited you to give to us?” Click here to make a donation.

More News
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...
27 Jun 2019
-- Globe Newswire reported on June 20th -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today...
5 Jun 2019
**Update: The US FDA Antimicrobial Drug Advisory Committee voted in favor of the NDA 14 to 4 on June 6th, 2019** The United States Food & Drug Administration (FDA) will host the Antimicrobial Drug Advisory Committee on Thursday, June 6th to discuss the new drug application (NDA) involving new...